Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leucovorin for Language Impairment in Children With Autism Spectrum Disorder
NCT02839915Phase 2Active, not recruiting
- Sponsor
- Southwest Autism Research & Resource Center
- Start
- Aug 2020
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Folinic Acid with Placebo Control (2 arms). Primary endpoints: Clinical Evaluation of Language Fundamentals 4 at Week 12 and Clinical Evaluation of Language Fundamentals Preschool at Week 12. Started Aug 2020; status: active, not recruiting.
02
Drugs
folinic acid
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02839915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839915.